The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)



Gene Review

Ddah1  -  dimethylarginine dimethylaminohydrolase 1

Rattus norvegicus

Synonyms: DDAH-1, DDAHI, Ddah, Dimethylargininase-1, Dimethylarginine dimethylaminohydrolase 1, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Ddah1


Psychiatry related information on Ddah1

  • The preservation of DDAH activity and the reduction of ADMA accumulation in neurons may be a new strategy for the treatment of Alzheimer's disease and cognitive impairment in normal aging [5].

High impact information on Ddah1

  • Dimethylargininase metabolizes ADMA to L-citrulline and plays a key role in determining the in vivo levels of ADMA [6].
  • RESULTS: Compared with HS rats, there was a significant (P < 0.05) increase in LS rats of nNOS protein in kidney and immunohistochemical expression in the macula densa, and of eNOS protein expression and immunohistochemical expression in the microvascular endothelium, and of DDAH protein expression [7].
  • Losartan prevented these effects of salt on the expression of eNOS or DDAH, both of which were also increased by Ang II infusions in HS rats [7].
  • Renal expression of constitutive NOS and DDAH: separate effects of salt intake and angiotensin [7].
  • In conclusion, sites of DDAH expression in the vasculature or nephron are all sites of expression of an isoform of NOS [8].

Biological context of Ddah1


Anatomical context of Ddah1

  • This data demonstrates that dimethylarginine dimethylaminohydrolase plays a pivotal role in tumour growth and the development of the tumour vasculature by regulating the concentration of nitric oxide and altering vascular endothelial cell growth factor production [1].
  • DDAH1 was also detected in the brain, kidney, digestive tract, and in other tissues [3].
  • Immunostaining for DDAH was present in PT, TAL, MD, and IC, and was also present in the glomerulus, Bowman's capsule, and endothelium of blood vessels [8].
  • Therefore, DDAH may regulate the cellular L-arginine: methylarginine levels in specific renal cells, thereby governing cell-specific L-arginine uptake and NO generation in renal tubular epithelium [8].
  • Incubation of lysed red blood cell (RBC) supernatant yielded a significant decrease in ADMA that was blocked by 4124W, a synthetic inhibitor of dimethylarginine dimethylaminohydrolase, the only reported enzyme to hydrolyze ADMA [12].

Associations of Ddah1 with chemical compounds

  • Dimethylarginine dimethylaminohydrolase 1 (DDAH1) is an enzyme that metabolizes methylated arginine to citrulline and methylamine, thus working to produce nitric oxide (NO) [3].
  • CONCLUSION: The expressions of eNOS in cortical microvascular endothelium and DDAH in kidney are enhanced by Ang II acting on AT(1) receptors [7].
  • It is concluded that L-homocysteine inhibits DDAH activity, thereby causing ADMA accumulation and decreasing nitric oxide production in cultured neurons [5].
  • The addition of PDTC caused a dose-dependent increase in DDAH activity [5].
  • In this study, we identified a cellular neurofibromin-associating protein, N(G),N(G)-dimethylarginine dimethylaminohydrolase (DDAH) that is known as a cellular NO/NOS regulator [10].

Other interactions of Ddah1


Analytical, diagnostic and therapeutic context of Ddah1


  1. Dimethylarginine dimethylaminohydrolase I enhances tumour growth and angiogenesis. Kostourou, V., Robinson, S.P., Cartwright, J.E., Whitley, G.S. Br. J. Cancer (2002) [Pubmed]
  2. Overexpression of dimethylarginine dimethylaminohydrolase enhances tumor hypoxia: an insight into the relationship of hypoxia and angiogenesis in vivo. Kostourou, V., Troy, H., Murray, J.F., Cullis, E.R., Whitley, G.S., Griffiths, J.R., Robinson, S.P. Neoplasia (2004) [Pubmed]
  3. Expression of DDAH1 in chick and rat embryos. Mishima, T., Hamada, T., Ui-Tei, K., Takahashi, F., Miyata, Y., Imaki, J., Suzuki, H., Yamashita, K. Brain Res. Dev. Brain Res. (2004) [Pubmed]
  4. Metabolism of asymmetric dimethylarginines is regulated in the lung developmentally and with pulmonary hypertension induced by hypobaric hypoxia. Arrigoni, F.I., Vallance, P., Haworth, S.G., Leiper, J.M. Circulation (2003) [Pubmed]
  5. Homocysteine increases the production of asymmetric dimethylarginine in cultured neurons. Selley, M.L. J. Neurosci. Res. (2004) [Pubmed]
  6. Asymmetrical dimethylarginine, an endogenous nitric oxide synthase inhibitor, in experimental hypertension. Matsuoka, H., Itoh, S., Kimoto, M., Kohno, K., Tamai, O., Wada, Y., Yasukawa, H., Iwami, G., Okuda, S., Imaizumi, T. Hypertension (1997) [Pubmed]
  7. Renal expression of constitutive NOS and DDAH: separate effects of salt intake and angiotensin. Tojo, A., Kimoto, M., Wilcox, C.S. Kidney Int. (2000) [Pubmed]
  8. Colocalization of demethylating enzymes and NOS and functional effects of methylarginines in rat kidney. Tojo, A., Welch, W.J., Bremer, V., Kimoto, M., Kimura, K., Omata, M., Ogawa, T., Vallance, P., Wilcox, C.S. Kidney Int. (1997) [Pubmed]
  9. Dimethylarginine dimethylaminohydrolase (DDAH) as a nerve-injury-associated molecule: mRNA localization in the rat brain and its coincident up-regulation with neuronal NO synthase (nNOS) in axotomized motoneurons. Nakagomi, S., Kiryu-Seo, S., Kimoto, M., Emson, P.C., Kiyama, H. Eur. J. Neurosci. (1999) [Pubmed]
  10. Phosphorylation of neurofibromin by cAMP-dependent protein kinase is regulated via a cellular association of N(G),N(G)-dimethylarginine dimethylaminohydrolase. Tokuo, H., Yunoue, S., Feng, L., Kimoto, M., Tsuji, H., Ono, T., Saya, H., Araki, N. FEBS Lett. (2001) [Pubmed]
  11. Demethylbellidifolin preserves endothelial function by reduction of the endogenous nitric oxide synthase inhibitor level. Jiang, D.J., Jiang, J.L., Zhu, H.Q., Tan, G.S., Liu, S.Q., Xu, K.P., Li, Y.J. Journal of ethnopharmacology. (2004) [Pubmed]
  12. Contribution of whole blood to the control of plasma asymmetrical dimethylarginine. Billecke, S.S., Kitzmiller, L.A., Northrup, J.J., Whitesall, S.E., Kimoto, M., Hinz, A.V., D'Alecy, L.G. Am. J. Physiol. Heart Circ. Physiol. (2006) [Pubmed]
  13. Evidence for dysregulation of dimethylarginine dimethylaminohydrolase I in chronic hypoxia-induced pulmonary hypertension. Millatt, L.J., Whitley, G.S., Li, D., Leiper, J.M., Siragy, H.M., Carey, R.M., Johns, R.A. Circulation (2003) [Pubmed]
  14. Pioglitazone lowers systemic asymmetric dimethylarginine by inducing dimethylarginine dimethylaminohydrolase in rats. Wakino, S., Hayashi, K., Tatematsu, S., Hasegawa, K., Takamatsu, I., Kanda, T., Homma, K., Yoshioka, K., Sugano, N., Saruta, T. Hypertens. Res. (2005) [Pubmed]
WikiGenes - Universities